Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Chowdhury, Mohammed Y E ^a,d   Li, Rui ^a   Kim, Jae Hoon ^a   Park, Min Eun ^a   Kim, Tae Hwan ^a   Pathinayake, Prabuddha ^a   Weeratunga, Prasanna ^a   Song, Man Ki ^b   Son, Hwa Young ^a   Hong, Seung Pyo ^c   Sung, Moon Hee ^c   Lee, Jong Soo ^a   Kim, Chul Joong ^a  

^a Chungnam National University   (South Korea)

^b International Vaccine Institute   (South Korea)

^c Bioleaders Corporation   (South Korea)

^d Chittagong Government Veterinary College   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 4; RECOMBINANT LACTOBACILLUS CASEI CHOLERA TOXIN SUBUNIT A1 CONJUGATED CONSENSUS MATRIX PROTEIN 2 CONJUGATE; RECOMBINANT LACTOBACILLUS CASEI CONSENSUS MATRIX PROTEIN 2 CONJUGATE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DRUG CONJUGATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE MICROSCOPY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA A (H5N2); INFLUENZA A (H7N3); INFLUENZA A (H9N2); INFLUENZA VACCINATION; MOUSE; MUCOSAL IMMUNITY; MUCOSAL INFLUENZA VACCINATION; NONHUMAN; OUTCOME ASSESSMENT; STRUCTURE ACTIVITY RELATION; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; INFLUENZA VIRUS A; LACTOBACILLUS CASEI; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; VACCINATION;

ANIMALS; FEMALE; INFLUENZA A VIRUS; INFLUENZA VACCINES; LACTOBACILLUS CASEI; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 84899517535     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094051     Document Type: Article

References (57)

1. Fiore AE, Bridges CB, Cox NJ (2009) Seasonal influenza vaccines. Curr Top Microbiol Immunol 333:43-82.
2. Kang SM, Song JM, Compans RW (2011) Novel vaccines against influenza viruses. Virus Res 162: 31-38.
3. Beyer WEP, Palache AM, Jong JCD, Osterhaus ADME (2002) Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy A meta-analysis. Vaccine 20:1340-1353. (Pubitemid 34131675)
4. Couch RB (2008) Seasonal inactivated influenza virus vaccines. Vaccine 26S:5-9.
5. Wright PF, Webster R (2001) Orthomyxoviruses. In: Knipe D.M, Howley PM, editors. Fields Virology: Lippncott Williams & Wilkins Press, Philadelphia. pp. 1533-1579.
6. Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, et al. (2008) CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-1252.
7. Frace AM, Kilmov AI, Rowe T, Black RA, Katz JM (1999) Modified M2 proteins produce heterotypic immunity against influenza virus. Vaccine 17: 2237-2244. (Pubitemid 29225675)
8. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, et al. (2007) Vaxfectin formulated influenza DNA vaccines encodingNP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 3: 157-164. (Pubitemid 47598172)
9. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, et al. (2008) Plasmid DNA based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197: 1643-1652. (Pubitemid 351919627)
10. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426-435. (Pubitemid 46348126)
11. Wu F, Huang JH, Yuan XY, huang WS, Chen YH (2007) Characterization of immunity induced by M2e of influenza virus. Vaccine 25: 8868-8873. (Pubitemid 350199590)
12. Ionescu RM, Przysiecki CT, Liang X, Garsky VM, Fan J, et al. (2006) Pharmaceutical and immunological evaluation of human papillomavirus virus like particle as an antigen carrier. J Pharm Sci 95:70-79.
13. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza m2e to the TLR5 ligand flagellin. Vaccine 26: 201-214. (Pubitemid 50008089)
14. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W (2007) Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 4: 118.
15. Quan FS, Ko EJ, Kwon YM, Joo KH, Compans RW, et al. (2013) Mucosal Adjuvants for Influenza Virus-Like Particle Vaccine. Viral Immunol 26: 385- 395.
16. Dickinson BL, Clements JD (1995) Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63: 1617-1623.
17. Lee JS, Poo H, Han DP, Hong SP, Kim K, et al. (2006) Mucosal immunization with surface displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 80: 4079-4087.
18. Mannam P, jones KF, Geller BL (2004) Mucosal vaccine made from live, recombinant Lactobacillus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 72: 3444-3450.
19. Lei H, Xu Y, Chen J, Wei X, Lam DM (2010) Immunoprotection against influenza H5N1 virus by oral administration of eneteric coated recombinant Lactococcus lactis mini-capsules. Virology 407: 319-324.
20. Lee JS, Shin KS, Pan JG, Kim CJ (2000) Surface displayed viral antigens on salmonella carrier vaccine. Nat Biotechnol 18: 645-648.
21. + T cells and antiviral protective immunity. J Virol 75: 9665-9670.
22. Shaw DM, Gaerthé B, Leer RJ, Van Der Stap JG, Smittenaar C, et al. (2000) Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of the tetanus toxin fragment C-expressing lactobacilli. Immunology 100: 510-518. (Pubitemid 30608505)
23. Xin KQ, Hoshino Y, Toda Y, Igimi S, Kojima Y, et al. (2003) Immunogenecity and protective efficacy of oral administered recombinant Lactobacillus lactis expressing surface bound HIV Env. Blood 102: 223-228. (Pubitemid 36759658)
24. Narita J, Okano K, Kitao T, Ishida S, Sewaki T, et al. (2006) Display of a-amylase on the surface of lactobacillus casei cells by use of the PgsA anchor protein, and production of lactic acid from starch. Appl Environ Microbiol 72: 269-275.
25. Candela T, Fouet A (2006) Poly-gamma-glutamate in bacteria. Mol Microbiol 60: 1091-1098. (Pubitemid 43922223)
26. Poo H, Pyo HM, Lee TY, Yoon SW, Lee JS, et al. (2006) Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. Int J Cancer 119: 1702-1709. (Pubitemid 44258780)
27. Qiu LD, Wei GJ, Yuan QX, Ping JY, Mei LS, et al. (2012) High-level mucosal and systemic immune responses induced by oral administration with Lactobacillus- expressed porcine epidemic diarrhea virus (PEDV) S1 region combined with Lactobacillus-expressed N protein. Appl Microbiol Biotechnol 93: 2437-2446.
28. Dieye Y, Usai S, Clier F, Gruss A, Piard JC (2001) Design of protein-targeting system for lactic acid bacteria. J Bacteriol 183: 4157-4166. (Pubitemid 32568066)
29. Sui Z, Chen Q, Wu R, Zhang H, Zheng M, et al. (2010) Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol 155: 535-544.
30. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, et al. (2011) Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza. PLoS ONE 6: e27953.
31. Oran AE, Robinson HL (2003) DNA vaccine combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4 producing CD4+ and CD8+ T cells. J Immunol 171: 1999-2005. (Pubitemid 36974544)
32. Moon HJ, Lee JS, Talactac MR, Chowdhury MY, Kim JH, et al. (2012) Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet Microbiol 160: 277-289.
33. Quan FS, Compans RW, Huang C, Kang SM (2007) Virus Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus. J Virol 81: 3514-3524. (Pubitemid 46456660)
34. Zhao G, Lin Y, Du L, Guan J, Sun S,et al. (2010) An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7: 2-8.
35. Itoh Y, Shinya K, Kiso M (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-5.
36. Ito T, Gorman O, Kawaoka Y, Bean W, Webster R (1991) Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 65: 5491-5498.
37. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W (2004) A "universal" human influenza A vaccine. Virus Res 103: 173-176.
38. Mohamadzadeh M, Olson S, Kalina WV, Ruthel G, Demmin GL, et al. (2005) Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci 102: 2880-2885. (Pubitemid 40299885)
39. Kim MC, Lee JS, Kwon YM, Eunju O, Lee YJ, et al. (2013) Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res 99: 328-335.
40. Frace AM, Klimova AI, Rowea T, Blacka RA, Katza JM (1999) Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17: 2237-2244. (Pubitemid 29225675)
41. Bermúdez-Humarán LG (2009) Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 504: 264-267.
42. Bermúdez-Humarán LG, Aubry C, Motta JP, Deraison C, et al. (2013) Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 16: 278-283.
43. Agren L, Lowenadler B, Lycke N (1998) A novel concept in mucosal adjuvanticity: The CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol Cell Biol 76: 280-287. (Pubitemid 28281156)
44. De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, et al. (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544-51. (Pubitemid 43017819)
45. Eriksson AM, Schon KM, Lycke NY (2004) The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 173: 3310-9. (Pubitemid 39142040)
46. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
47. Song MK (2010) A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines. World Intellectual Property Organization patent WO2010046783.
48. Wang Z, Yu Q, Gao J, Yang Q (2011) Mucosal and Systemic Immune Responses Induced by Recombinant Lactobacillus spp. Expressing the Hemagglutinin of the Avian Influenza Virus H5N1. Clin Vaccine Immunol 19: 174-179.
49. Wang R, Song A, Levin J, Dennis D, Zhang NJ, et al. (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80: 168-177.
50. Fu TM, Freed DC, Horton MS, Fan J, Citron MP, et al. (2009) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385: 218-226.
51. Jegerlehner A, Schmitz N, Storni T, Bachmann MF (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605. (Pubitemid 38542062)
52. Wu F, Yuan XY, Li J, Chen YH (2009) The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 27: 4320-4.
53. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512-6521.
54. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, et al. (2011) Influenza Virus-Like particles containing M2 induce broadly cross protective immunity. PLoS One 6: e14538.
55. Bakkouri KEl, Descamps F, Filette MD, Smet A, Festjens E, et al. (2011) Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection. J Immunol 186:1022-1031.
56. Zou P, Liu W, Chen YH (2005) The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol 5:631-635. (Pubitemid 40248318)
57. Bodewes R, Kreijtz JHCM, Baas C, Geelhoed-Mieras MM, de Mutsert G, et al. (2009) Vaccination against Human Influenza A/H3N2 Virus Prevents the Induction of Heterosubtypic Immunity against Lethal Infection with Avian Influenza A/H5N1 Virus. PLoS ONE 4:e5538.